Headshot of Gaelle Chapuis.

Gaëlle Chapuis

Director of operations and outreach
International Brain Laboratory

Gaëlle Chapuis is a director and technical manager responsible for overseeing the activities of the International Brain Laboratory, a global consortium of 21 institutions and more than 75 people, aimed at understanding how brain activity patterns lead to decision-making. Chapuis is based in Geneva and supervises a team of engineers deployed in five countries. Her group provides support to scientists, creating professionalized workflows that are adopted at a large scale. She also supervises the outreach efforts of the consortium. So far, more than 40 research projects in and outside of the International Brain Laboratory have benefited from these technologies and organizational developments.

After earning a B.Sc. in microengineering at the Swiss Federal Technology Institute of Lausanne (EPFL), Chapuis pursued an M.Sc. in biomedical engineering with a specialization in neurotechnology at Imperial College London. She then undertook several research projects in the field of sensory neuroscience at EPFL; the University of California, San Francisco; and University College London before completing a Ph.D. at Imperial College London in the laboratory of Paul Chadderton.

Explore more from The Transmitter

Headshots of Yale researchers Yong-Hui Jiang and Jiangbing Zhou.

Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions

Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.

By Natalia Mesa
3 June 2026 | 11 min read

What counts as a ‘naturalistic’ behavior?

Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.

By Paul Middlebrooks
3 June 2026 | 1 min read
Research image of brain cells involved with Amyotrophic lateral sclerosis (ALS) illuminated through genetic tools

Allen Institute sets sights on treatments for five brain diseases

The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.

By Calli McMurray
2 June 2026 | 5 min read